Furthermore, lower ACAA1 expression was shown to be associated the resistance of NSCLC cell lines to five different anti-cancer drugs including AZD0530, AZD6244, ZD-6474, Erlotinib and Lapatinib, providing new clues for NSCLC chemotherapy. Here, ACAA1 is linked to cancer.